Anti-(homo Sapiens Alpha-synuclein)humanized Monoclonal Antibody.gamma.1 Heavy Chain (1-442) (homo Sapiens Vh (ighv3-25*03 (86%) (ighd)-ighj2*01) (8.10.4) (1-113)-homo Sapiens Ighg1*03 (ch3(k107>del(443))) (114-442)) (216-213')- is under investigation in clinical trial NCT03318523 (Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease).
| Trade Name |
Anti-(homo Sapiens Alpha-synuclein)humanized Monoclonal Antibody.gamma.1 Heavy Chain (1-442) (homo Sapiens Vh (ighv3-25*03 (86%) (ighd)-ighj2*01) (8.10.4) (1-113)-homo Sapiens Ighg1*03 (ch3(k107>del(443))) (114-442)) (216-213')- |
| Generic |
Cinpanemab |
| Cinpanemab Other Names |
Cinpanemab, Immunoglobulin g1-lambda, anti-(homo sapiens alpha-synuclein)humanized monoclonal antibody.gamma.1 heavy chain (1-442) (homo sapiens vh (ighv3-25*03 (86%) (ighd)-ighj2*01) (8.10.4) (1-113)-homo sapiens ighg1*03 (ch3(k107>del(443))) (114-442)) (216-213')-, Immunoglobulin g1-lambda, anti-(homo sapiens snca (synuclein alpha, alpha-synuclein, park1, park4, parkinson disease (autosomal dominant, lewy body) 4, non a4 component of amyloid precursor, nacp)), monoclonal antibodygamma1 heavy chain (1-442) (vh (homo, Immunoglobulin g1, anti-(human .alpha.-synuclein) (human monoclonal biib054 .gamma.1-chain), disulfide with human monoclonal biib054 .kappa.-chain, dimer |
| Type |
|
| Groups |
Investigational |
| Therapeutic Class |
|
| Manufacturer |
|
| Available Country |
|
| Last Updated: |
January 7, 2025 at 1:49 am |
Innovators Monograph
